Torsade de pointes due to dronedarone: Déjà Vu?

Pharmacotherapy

Volumn 32, Issue 8, 2012, Pages 764-766

  Bauman, Jerry L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Dronedarone; Proarrhythmia; Sudden cardiac death; Torsade de pointes

Indexed keywords

AMIODARONE; DRONEDARONE; PLACEBO; QUINIDINE; SOTALOL;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; DISEASE ASSOCIATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART REPOLARIZATION; HUMAN; PAROXYSMAL TACHYCARDIA; REVIEW; RISK FACTOR; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; HUMANS;

EID: 84864600320     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01140.x     Document Type: Review

References (16)

1. Viko LE, Marvin HM, White PD. Clinical report on the use of quinidine sulfate. Arch Intern Med 1923;31:345-63.
2. Selzer A, Wray HW. Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17-26.
3. Dessertenne F. Ventricular tachycardia with two variable opposing foci [in French]. Arch Mal Coeur Vaiss 1966;59:263-72.
4. Bauman JL, Baurenfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsade de pointes due to quinidine: Observations in 31 patients. Am Heart J 1984;107:425-30.
5. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986;111:1088-93.
6. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on morality in patients with left ventricular dysfunction and remote myocardial infarction. Lancet 1996;348:7-12.
7. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized controlled trials. Circulation 1990;82:1106-16.
8. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo: The cardiac arrhythmia suppression trial. N Engl J Med 1991;324:781-8.
9. Kao DP, Hiatt WR, Krantz MJ. Proarrhythmic potential of dronedarone: Emerging evidence from spontaneous adverseevent reporting. Pharmacotherapy 2012;32:767-771.
10. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: Data mining of the public version of the FDA adverse event reporting system (AERS). Pharmacoepidemiol Drug Saf 2009;18:512-8.
11. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
12. Gallastegui JL, Bauman JL, Anderson JL, et al. Worsening of ventricular tachycardia by amiodarone. J Clin Pharmacol 1988;28:406-11.
13. van Opstal JM, Schoenmakers M, Verduyn C, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long QT syndrome. Circulation 2001;104:2722-7.
14. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Dronedrone in patients with congestive heart failure: Insights from ATHENA. Eur Heart J 2010;31:1717-21.
15. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.
16. Connolly SJ, Camm AJ, Halerin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76.